Key Performance
More- Earnings Score: N/A
- Momentum Score: 53
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Kelyniam Global, Inc. (OTC:KLYG), a leader in patient-specific cranial and craniofacial implants, announced it will present at Planet MicroCap Las Vegas 2026 on June 17, 2026. The company highlighted strong Q1 2026 financial performance with revenue of $1.15 million (+84% YoY) and gross profit growth of 105%. Key developments include the FDA-cleared Fusion™ BCP-PEEK implant launch and expansion of its regenerative medicine portfolio.
06/01/2026, 12:01 AM • Benzinga
Kelyniam Global Announces Strong Q1 2026 Financial Results
Kelyniam Global (OTC:KLYG) reported strong Q1 2026 results with total revenue of $1.15M (84% YoY increase), gross profit of $962.8K (105% increase), and a return to operating profitability of $295.3K from a prior-year loss. CustomizedBone™ implant sales grew over 50%, and the company successfully implanted its first Fusion PEEK+BCP implant during the quarter.
05/11/2026, 12:01 AM • Benzinga
Kelyniam Global Reports 2025 Financial Results
Kelyniam Global (OTC:KLYG) reported 2025 financial results showing an 85% improvement in net loss to $(138,555) despite an 8% revenue decline to $3.05M. The company secured FDA clearance for its innovative Fusion™ cranial implants using next-generation VESTAKEEP® Fusion biomaterial and rejected an undervalued acquisition offer, reaffirming commitment to long-term shareholder value.
03/16/2026, 12:01 AM • Benzinga
Kelyniam Global has obtained an exclusive two-year U.S. license from Evonik Industries to market VESTAKEEP® Fusion, a bi-calcium phosphate-infused PEEK material for cranial and craniofacial implants, expanding its regenerative medicine portfolio.
11/13/2025, 12:47 PM • GlobeNewswire
Kelyniam Global Announces Q3 2025 Financial Results
Kelyniam Global reported Q3 2025 financial results with decreased revenue and an operating loss, but remains optimistic about growth in the cranial implant sector through new product clearances and distributor expansion.
11/10/2025, 3:55 PM • Benzinga
Kelyniam Global has renewed its licensing agreement with Finceramica for three years, gaining exclusive access to advanced biomaterials like SINTlife, a fully resorbable synthetic graft expected to receive FDA clearance within two years.
11/06/2025, 7:09 PM • GlobeNewswire
Kelyniam Global Inc. to Present at the Life Sciences Virtual Investor Forum September 18th
Kelyniam Global Inc. will present at the Life Sciences Virtual Investor Forum on September 18th, 2025, showcasing their custom cranial implants and new product line enhancements.
09/15/2025, 12:01 AM • Benzinga
Kelyniam Global Inc. has been elevated to OTCID status on the OTC Markets Group platform, signaling improved transparency and compliance in its financial reporting.
09/08/2025, 12:01 AM • Benzinga
Kelyniam Global Announces Q2 2025 Financial Results
Kelyniam Global reported Q2 2025 financial results with total revenue of $1,364,432, a 20.2% decrease from Q2 2024. The company experienced a slower first quarter but saw improved sales execution in Q2, particularly in the custom cranial and craniofacial implant market.
08/11/2025, 11:16 AM • Benzinga